Publications by authors named "Nuttanun Wongsarikan"
Article Synopsis
- * A study involving 30 MHD patients compared three different vaccine regimens, analyzing plasma samples for 92 metabolomic levels before and after vaccination, revealing that vaccine type affected metabolomic profiles.
- * Key findings highlighted that certain amino acids and phospholipids were associated with neutralizing antibody levels post-vaccination, suggesting that phospholipid metabolism could serve as a potential predictor for vaccine effectiveness in MHD patients.
Correction: Narongkiatikhun et al. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. 2023, , 175.
Phoom Narongkiatikhun Kajohnsak Noppakun Romanee Chaiwarith Poramed Winichakoon Surachet Vongsanim Nuttanun Wongsarikan
Vaccines (Basel)
September 2023
The authors wish to make the following correction to this paper [...
View Article and Find Full Text PDFImmunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study.
Phoom Narongkiatikhun Kajohnsak Noppakun Romanee Chaiwarith Poramed Winichakoon Surachet Vongsanim Nuttanun Wongsarikan
Vaccines (Basel)
March 2023
Background: Vaccines that prevent SARS-CoV-2 infection are considered the most promising approach to modulating the pandemic. There is scarce evidence on the efficacy and safety of different vaccine prime-boost combinations in MHD patients since most clinical trials have used homologous mRNA vaccine regimens.
Methods: This prospective observational study assessed the immunogenicity and safety of homologous CoronaVac (SV-SV), ChAdOx1 nCoV-19 (AZD1222) (AZ-AZ), and the heterologous prime-boost of SV-AZ, among MHD patients.